View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Antero Resources Corp: 2 directors

Two Directors at Antero Resources Corp sold after exercising options/sold 34,667 shares at between 38.130USD and 39.330USD. The significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by a...

Comstock Resources Inc: 1 director

A director at Comstock Resources Inc sold 48,915 shares at 21.205USD and the significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...

 PRESS RELEASE

Victoria’s Secret & Co. Reports 2025 Fourth Quarter and Full Year Resu...

Victoria’s Secret & Co. Reports 2025 Fourth Quarter and Full Year Results Fourth Quarter and Full Year Results Exceeded Top- and Bottom-line GuidanceComparable Sales Increased 8% in the Fourth Quarter and 5% for the Full YearFourth Quarter and Full Year Adjusted Operating Income Significantly Exceeded ExpectationsInitiates First Quarter and Fiscal 2026 Guidance REYNOLDSBURG, Ohio, March 05, 2026 (GLOBE NEWSWIRE) -- Victoria’s Secret & Co. (“VS&Co” or the “Company”) (NYSE: VSCO) today reported financial results for the fourth quarter and fiscal year ended January 31, 2026. Hillary Super,...

Expand Energy Corporation: Diversified asset base with improving cash ...

Our credit view of this issuer reflects its large proved reserves and production scale, against its lack of commodity diversification with dry natural gas focus.

 PRESS RELEASE

HII’s Ingalls Shipbuilding Authenticates Keel of Philadelphia (LPD 32)

HII’s Ingalls Shipbuilding Authenticates Keel of Philadelphia (LPD 32) PASCAGOULA, Miss., March 03, 2026 (GLOBE NEWSWIRE) -- HII’s (NYSE: HII) Ingalls Shipbuilding division authenticated the keel today for the future USS Philadelphia (LPD 32), a Flight II San Antonio-class amphibious transport dock ship. The ceremony included ship sponsor Maureen Paparo, a Philadelphia native, who was joined by her spouse, Adm. Samuel Paparo, commander U.S. Indo-Pacific Command. Also, attending the ceremony was Chris Kastner, HII’s president and CEO, Brian Blanchette, Ingalls Shipbuilding president and k...

Northrop Grumman Corp: 2 directors

A director at Northrop Grumman Corp sold/sold after exercising options 873 shares at 745.000USD and the significance rating of the trade was 92/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directo...

David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan

Hanover Insurance Group Inc: 1 director

A director at Hanover Insurance Group Inc sold 1,200 shares at 180.910USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...

Wedbush Research
  • Wedbush Research
W WAYFAIR INC.
UBI UBISOFT ENTERTAINMENT SA
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
TRIP TRIPADVISOR INC.
SRPT SAREPTA THERAPEUTICS INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
MELI MERCADOLIBRE INC.
KURA KURA ONCOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FB FACEBOOK INC. CLASS A
FATE FATE THERAPEUTICS INC
EXPE EXPEDIA GROUP INC.
ETSY ETSY INC.
EBAY EBAY INC.
CTMX CYTOMX THERAPEUTICS INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
CDR CD PROJEKT S.A.
FRX_CN FENNEC PHARMACEUTICALS
7974 NINTENDO CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
EA ELECTRONIC ARTS INC.
PTGX PROTAGONIST THERAPEUTICS
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
OVID OVID THERAPEUTICS
ISR ISORAY
SE SEA ADS
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
APLS APELLIS PHARMACEUTICALS
BKNG BOOKING HOLDINGS INC.
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
STRO SUTRO BIOPHARMA
LYFT LYFT
PINS PINTEREST INC. CLASS A
UBER UBER TECHNOLOGIES INC.
CHWY CHEWY INC. CLASS A
STOK STOKE THERAPEUTICS
SMCI SUPER MICRO COMPUTER
IDYA INC.
PASG IDEAYA BIOSCIENCES
BDTX PASSAGE BIO
ACET BLACK DIAMOND THERAPEUTICS
KROS ADICET BIO INC
ZNTL KEROS THERAPEUTICS
BEAM ZENTALIS PHARMACEUTICALS
LRMR BEAM THERAPEUTICS
OCUP LARIMAR THERAPEUTICS INC
PRAX OCUPHIRE PHARMA INC
COGT PRAXIS PRECISION MEDICINES
U COGENT BIOSCIENCES INC
TVTX UNITY SOFTWARE
DASH TRAVERE THERAPEUTICS INC
ABNB DOORDASH
VRDN AIRBNB INC. CLASS A
PLTK VIRIDIAN THERAPEUTICS INC
NUVB PLAYTIKA HOLDING
RBLX NUVATION BIO INC (A)
DAWN ROBLOX
TNGX DAY ONE BIOPHARMACEUTICALS INC
STX TANGO THERAPEUTICS
HOWL INC
APP SEAGATE TECHNOLOGY HLDGS PLC
TTD WEREWOLF THERAPEUTICS INC
QUBT APPLOVIN CORP
GFS THE TRADE DESK
GMTX INC.
TYRA QUANTUM COMPUTING INC
EWTX GLOBALFOUNDRIES INC
SLDB GEMINI THERAPEUTICS INC
DDI TYRA BIOSCIENCES INC
APGE EDGEWISE THERAPEUTICS INC
EMBRAC B SOLID BIOSCIENCES INC
DNTH DOUBLEDOWN INTERACTIVE CO LTD
CART APOGEE THERAPEUTICS INC
NATL EMBRACER GROUP AB
CGON DIANTHUS THERAPEUTICS INC
ORKA MAPLEBEAR INC.
BCAX NCR ATLEOS CORPORATION
ZBIO CG ONCOLOGY INC
TLX ORUKA THERAPEUTICS INC
MAZE BICARA THERAPEUTICS INC.
JBIO ZENAS BIOPHARMA INC.
TELIX PHARMACEUTICALS LIMITED
MAZE THERAPEUTICS INC
JADE BIOSCIENCES INC
David Nierengarten ... (+8)
  • David Nierengarten
  • Dennis Pak
  • Geoffrey Von Der Ahe
  • Laura Chico
  • Martin Fan
  • Robert Driscoll
  • Thomas Yip
  • Yun Zhong
Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: February 28, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

David Nierengarten ... (+8)
  • David Nierengarten
  • Dennis Pak
  • Geoffrey Von Der Ahe
  • Laura Chico
  • Martin Fan
  • Robert Driscoll
  • Thomas Yip
  • Yun Zhong
Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: February 27, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Independent Bank Corp Mi: 1 director

A director at Independent Bank Corp Mi bought 1,200 shares at 35.270USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...

Moody's Ratings affirms Pilgrim's Pride's Ba2 CFR; outlook revised to ...

Moody's Ratings (Moody's) affirmed Pilgrim's Pride Corporation's ("Pilgrim's") Ba2 Corporate Family Rating ("CFR"), Ba2-PD Probability of Default Rating, Ba2 senior unsecured notes rating, and (P)Ba2 senior unsecured shelf rating. The speculative grade liquidity rating is unchanged at SGL-1. We revi...

 PRESS RELEASE

ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Resul...

ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company anticipates multiple meaningful data sets and milestones in the coming 12 to 18 months - - Evorpacept biomarker strategy validated by data from both the Phase 2 ASPEN-06 gastric cancer trial and the Phase 1b/2 breast cancer trial, independently suggesting CD47 overexpression is predictive of evor...

 PRESS RELEASE

Chemed Reports Fourth-Quarter 2025 Results

Chemed Reports Fourth-Quarter 2025 Results CINCINNATI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its fourth quarter ended December 31, 2025, versus the comparable prior-year period. Results for Quarter Ended December 31, 2025 Consolidated operating results: Revenue was $639.3 million, essentially flat with the...

Moody's Ratings says Gilead's acquisition of Arcellx improves diversit...

Moody's Ratings (Moody's) said that Gilead Sciences, Inc.'s ("Gilead"; A3 positive) acquisition of Arcellx will improve Gilead's product and therapeutic diversity through full ownership of its key cell therapy pipeline product anito-cel for multiple myeloma. Gilead announced on 23 February that it e...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch